{"id":9293,"date":"2024-12-10T11:33:26","date_gmt":"2024-12-10T10:33:26","guid":{"rendered":"https:\/\/www.seventure.fr\/?p=9293"},"modified":"2025-01-09T11:36:47","modified_gmt":"2025-01-09T10:36:47","slug":"maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/","title":{"rendered":"MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[101,105],"tags":[],"class_list":["post-9293","post","type-post","status-publish","format-standard","hentry","category-life-sciences-en","category-microbiome-nutrition-foodtech-lifestyle"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting | Seventure<\/title>\n<meta name=\"description\" content=\"These findings underscore MaaT013\u2019s potential as a transformative therapy for aGvHD, a condition with poor survival rates and limited treatment options. The high response rates and long-term survival data further validate the critical role of the gut microbiome modulation in managing aGvHD. Additionally, these results highlight the growing interest within the medical community, as demonstrated by ASH\u2019s dedicated symposium on the microbiome\u2019s role in transplantation and cellular therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Romane Brunet\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\\\/\"},\"author\":{\"name\":\"Romane Brunet\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#\\\/schema\\\/person\\\/990cba5bd0870778fd29b092bb2bacd5\"},\"headline\":\"MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting\",\"datePublished\":\"2024-12-10T10:33:26+00:00\",\"dateModified\":\"2025-01-09T10:36:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\\\/\"},\"wordCount\":17,\"articleSection\":[\"Life Sciences\",\"Microbiome \\\/ Nutrition \\\/ Foodtech \\\/ Lifestyle\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\\\/\",\"name\":\"MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting | Seventure\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#website\"},\"datePublished\":\"2024-12-10T10:33:26+00:00\",\"dateModified\":\"2025-01-09T10:36:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#\\\/schema\\\/person\\\/990cba5bd0870778fd29b092bb2bacd5\"},\"description\":\"These findings underscore MaaT013\u2019s potential as a transformative therapy for aGvHD, a condition with poor survival rates and limited treatment options. The high response rates and long-term survival data further validate the critical role of the gut microbiome modulation in managing aGvHD. Additionally, these results highlight the growing interest within the medical community, as demonstrated by ASH\u2019s dedicated symposium on the microbiome\u2019s role in transplantation and cellular therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.seventure.fr\\\/en\\\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/#\\\/schema\\\/person\\\/990cba5bd0870778fd29b092bb2bacd5\",\"name\":\"Romane Brunet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g\",\"caption\":\"Romane Brunet\"},\"url\":\"https:\\\/\\\/www.seventure.fr\\\/en\\\/author\\\/romane-brunet\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting | Seventure","description":"These findings underscore MaaT013\u2019s potential as a transformative therapy for aGvHD, a condition with poor survival rates and limited treatment options. The high response rates and long-term survival data further validate the critical role of the gut microbiome modulation in managing aGvHD. Additionally, these results highlight the growing interest within the medical community, as demonstrated by ASH\u2019s dedicated symposium on the microbiome\u2019s role in transplantation and cellular therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/","twitter_misc":{"Written by":"Romane Brunet"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/"},"author":{"name":"Romane Brunet","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5"},"headline":"MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting","datePublished":"2024-12-10T10:33:26+00:00","dateModified":"2025-01-09T10:36:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/"},"wordCount":17,"articleSection":["Life Sciences","Microbiome \/ Nutrition \/ Foodtech \/ Lifestyle"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/","url":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/","name":"MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2024-12-10T10:33:26+00:00","dateModified":"2025-01-09T10:36:47+00:00","author":{"@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5"},"description":"These findings underscore MaaT013\u2019s potential as a transformative therapy for aGvHD, a condition with poor survival rates and limited treatment options. The high response rates and long-term survival data further validate the critical role of the gut microbiome modulation in managing aGvHD. Additionally, these results highlight the growing interest within the medical community, as demonstrated by ASH\u2019s dedicated symposium on the microbiome\u2019s role in transplantation and cellular therapies.","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/en\/maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seventure.fr\/en\/#\/schema\/person\/990cba5bd0870778fd29b092bb2bacd5","name":"Romane Brunet","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/efe58eeb7d12f67249bb906294dace961dd1ea505113759a9a2820da1ffaa1ec?s=96&d=mm&r=g","caption":"Romane Brunet"},"url":"https:\/\/www.seventure.fr\/en\/author\/romane-brunet\/"}]}},"_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=9293"}],"version-history":[{"count":0,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/posts\/9293\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media?parent=9293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/categories?post=9293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/tags?post=9293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}